ESC: Johnson & Johnson hunts for silver lining as Xarelto bombs blood clot, heart failure studies

27th August 2018 Uncategorised 0

What a comedown for Johnson & Johnson’s Xarelto at the European Society of Cardiology annual meeting. Last year, J&J touted data that put the clot-buster on track for a new $1 billion-plus approval. This time, the company was forced to admit Xarelto had flopped—and not once, but twice.

More: ESC: Johnson & Johnson hunts for silver lining as Xarelto bombs blood clot, heart failure studies
Source: fierce